Up to now, the Food and Drug Administration has approved four CD19 CAR-T products for treating relapsed or refractory (R/R) hematological malignancies; axicabtagene-ciloleucel (Yescarta), tisagenlecleucel (Kymriah), brexucabtagene autoleucel (Tecartus), and lisocabtagene maraleucel (Breyanzi). This evidence concerns the gene CD19 and hematologic disorder.